Physician profile
Sarah H Vantassel
NPI 1982966974
$75,584.74
in general payments reported to CMS, 2019-2025
13 companies · $12K in 2025
The $12K reported for 2025 was more than what 93% of Glaucoma Specialist providers received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,163 · 2020: $5,642 · 2021: $15K · 2022: $3,184 · 2023: $17K · 2024: $20K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $42K · Honoraria: $4,300 · Food and Beverage: $2,364 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $900 · Travel and Lodging: $58.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $42,200.30 |
| Honoraria | $4,300.00 |
| Food and Beverage | $2,364.29 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $900.00 |
| Travel and Lodging | $58.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| New World Medical,INC. | $13,619.27 | 2019-2025 | Clearpath, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Glaukos Corporation | $12,587.67 | 2019-2025 | Istent Trabecular Micro-Bypass Stent System, Istent Infinite Trabecular Micro-Bypass System Model Is3, Idose Tr |
| Abbvie INC. | $12,546.62 | 2021-2025 | Durysta, Xen Glaucoma Treatment System, Lumigan |
| Carl Zeiss Meditec, INC. | $10,825.00 | 2021-2025 | Cirrus Hd-Oct, Callisto Eye, Cirrus 6000 With Angioplex |
| Alcon Research LLC | $7,347.85 | 2024-2025 | Centurion |
| Alcon Vision LLC | $5,665.28 | 2019-2024 | Hydrus Microstent, Simbrinza, Rhopressa |
| Thea Pharma INC. | $4,500.00 | 2023-2024 | Iyuzeh |
| Allergan, INC. | $3,482.35 | 2020-2021 | |
| Aerie Pharmaceuticals, INC. | $1,780.85 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $1,660.23 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,299.67 | 2021 | |
| Aspira Women'S Health INC | $151.84 | 2024 | Ova1 |
| Sight Sciences, INC. | $118.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Vantassel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.